Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Mesothelioma through trial conditions or approval indications mapped to it or to one of its descendant entities.
0 drugs · 0 active trials
no drug at this stage
4 drugs · 30 active trials
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab | Approved | Phase 3 | 10 | 2 | 1 | 27 | 1 | US | Sep 4, 2014 | Mar 31, 2015 |
| Pemetrexed | Approved | Phase 4 | 9 | 4 | 6 | 45 | 7 | US | Feb 4, 2004 | 1999-11 |
| Nivolumab | Approved | Phase 3 | 7 | 3 | 2 | 19 | 1 | US | Dec 22, 2014 | 2015-07 |
| Ipilimumab | Approved | Phase 3 | 4 | 1 | 1 | 8 | 1 | US | Mar 25, 2011 | Nov 29, 2016 |
| Cisplatin | Phase 3 | Phase 3 | 7 | 3 | 7 | 51 | 0 | — | — | 1994-05 |
| Carboplatin | Phase 3 | Phase 3 | 4 | 4 | 2 | 9 | 0 | — | — | Feb 23, 2006 |
| Gemcitabine | Phase 3 | Phase 3 | 2 | 0 | 2 | 18 | 0 | — | — | 1999-02 |
| Ipilimumab/Nivolumab Regimen | Phase 3 | Phase 3 | 2 | 2 | 1 | 4 | 0 | — | — | Mar 24, 2016 |
| Vinorelbine | Phase 3 | Phase 3 | 1 | 0 | 2 | 7 | 0 | — | — | 2000-11 |
| Durvalumab | Phase 3 | Phase 3 | 0 | 0 | 1 | 6 | 0 | — | — | May 11, 2016 |
| Chemotherapy | Phase 3 | Phase 3 | 0 | 0 | 2 | 5 | 0 | — | — | 1997-08 |
| Doxorubicin | Phase 3 | Phase 3 | 0 | 0 | 1 | 5 | 0 | — | — | 1994-05 |
| Mitomycin | Phase 3 | Phase 3 | 0 | 0 | 1 | 3 | 0 | — | — | 2000-11 |
| Nintedanib | Phase 3 | Phase 3 | 0 | 0 | 1 | 3 | 0 | — | — | Sep 19, 2013 |
| Raltitrexed | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 1999-11 |
| Vorinostat | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | Jun 30, 2005 |
| Nadofaragene Firadenovec | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | Jan 21, 2019 |
| Vincristine | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2003-09 |
| Cyclophosphamide | Phase 2 | Phase 2 | 5 | 2 | 0 | 16 | 0 | — | — | 1991-04 |
| Atezolizumab | Phase 2 | Phase 2 | 5 | 3 | 0 | 8 | 0 | — | — | Mar 3, 2017 |
| Bevacizumab | Phase 2 | Phase 2 | 3 | 2 | 0 | 6 | 0 | — | — | 2001-10 |
| Fludarabine | Phase 2 | Phase 2 | 3 | 2 | 0 | 6 | 0 | — | — | May 4, 2012 |
| Aldesleukin | Phase 2 | Phase 2 | 2 | 1 | 0 | 4 | 0 | — | — | May 4, 2012 |
| Lenvatinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Mar 1, 2021 |
| Tislelizumab | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Apr 12, 2021 |
| Cediranib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2005-11 |
| Enzalutamide | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Oct 4, 2018 |
| Hyperthermic Intraperitoneal Chemotherapy | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Nov 8, 2019 |
| Olaparib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Jul 11, 2018 |
| Osimertinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Mar 24, 2021 |
| Brentuximab Vedotin | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Apr 5, 2017 |
| Cemiplimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 2, 2026 |
| Durvalumab/Tremelimumab Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jul 3, 2024 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 21, 2024 |
| Sotorasib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 27, 2026 |
| Therapeutic Tumor Infiltrating Lymphocytes | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Dec 3, 2019 |
| Tremelimumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2009-05 |
| Dexamethasone | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2006-08 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2001-12 |
| Porfimer | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 1999-03 |
| Tazemetostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2016-07 |
| Abemaciclib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2012 |
| Bortezomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-05 |
| Celecoxib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Dec 7, 2010 |
| Dasatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2007-08 |
| Everolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2008-12 |
| Gefitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2001-09 |
| Imatinib Mesylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-08 |
| Lurbinectedin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | May 6, 2016 |
| Methotrexate | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2002-08 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.